725 related articles for article (PubMed ID: 28138040)
1. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive
Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA
J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040
[TBL] [Abstract][Full Text] [Related]
2. In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu
Witkin JM; Ornstein PL; Mitch CH; Li R; Smith SC; Heinz BA; Wang XS; Xiang C; Carter JH; Anderson WH; Li X; Broad LM; Pasqui F; Fitzjohn SM; Sanger HE; Smith JL; Catlow J; Swanson S; Monn JA
Neuropharmacology; 2017 Mar; 115():100-114. PubMed ID: 26748052
[TBL] [Abstract][Full Text] [Related]
3. Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.
Chappell MD; Li R; Smith SC; Dressman BA; Tromiczak EG; Tripp AE; Blanco MJ; Vetman T; Quimby SJ; Matt J; Britton TC; Fivush AM; Schkeryantz JM; Mayhugh D; Erickson JA; Bures MG; Jaramillo C; Carpintero M; Diego JE; Barberis M; Garcia-Cerrada S; Soriano JF; Antonysamy S; Atwell S; MacEwan I; Condon B; Sougias C; Wang J; Zhang A; Conners K; Groshong C; Wasserman SR; Koss JW; Witkin JM; Li X; Overshiner C; Wafford KA; Seidel W; Wang XS; Heinz BA; Swanson S; Catlow JT; Bedwell DW; Monn JA; Mitch CH; Ornstein PL
J Med Chem; 2016 Dec; 59(24):10974-10993. PubMed ID: 28002967
[TBL] [Abstract][Full Text] [Related]
4. Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects.
Witkin JM; Monn JA; Li J; Johnson B; McKinzie DL; Wang XS; Heinz BA; Li R; Ornstein PL; Smith SC; Mitch CH; Calligaro DO; Swanson S; Allen D; Phillips K; Gilmour G
Pharmacol Biochem Behav; 2017 Apr; 155():43-55. PubMed ID: 28285123
[TBL] [Abstract][Full Text] [Related]
5. mGlu2/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effects.
Witkin JM
Pharmacol Biochem Behav; 2020 Mar; 190():172854. PubMed ID: 31954773
[TBL] [Abstract][Full Text] [Related]
6. The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits.
Witkin JM; Monn JA; Schoepp DD; Li X; Overshiner C; Mitchell SN; Carter G; Johnson B; Rasmussen K; Rorick-Kehn LM
J Pharmacol Exp Ther; 2016 Jul; 358(1):71-82. PubMed ID: 27189960
[TBL] [Abstract][Full Text] [Related]
7. The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice.
Pałucha-Poniewiera A; Podkowa K; Rafało-Ulińska A
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110239. PubMed ID: 33400944
[TBL] [Abstract][Full Text] [Related]
8. Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats.
Koike H; Chaki S
Behav Brain Res; 2014 Sep; 271():111-5. PubMed ID: 24909673
[TBL] [Abstract][Full Text] [Related]
9. Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test.
Fukumoto K; Iijima M; Chaki S
Psychopharmacology (Berl); 2014 Jun; 231(11):2291-8. PubMed ID: 24402133
[TBL] [Abstract][Full Text] [Related]
10. [The potential of group II metabotropic glutamate receptor antagonists as a novel antidepressant].
Chaki S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Aug; 32(4):219-26. PubMed ID: 23012890
[TBL] [Abstract][Full Text] [Related]
11. Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats.
Podkowa K; Pochwat B; Brański P; Pilc A; Pałucha-Poniewiera A
Psychopharmacology (Berl); 2016 Aug; 233(15-16):2901-14. PubMed ID: 27286960
[TBL] [Abstract][Full Text] [Related]
12. mGlu2/3 receptor as a novel target for rapid acting antidepressants.
Chaki S
Adv Pharmacol; 2020; 89():289-309. PubMed ID: 32616210
[TBL] [Abstract][Full Text] [Related]
13. Modulation by chronic stress and ketamine of ionotropic AMPA/NMDA and metabotropic glutamate receptors in the rat hippocampus.
Elhussiny MEA; Carini G; Mingardi J; Tornese P; Sala N; Bono F; Fiorentini C; La Via L; Popoli M; Musazzi L; Barbon A
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110033. PubMed ID: 32640261
[TBL] [Abstract][Full Text] [Related]
14. Impact of early-life stress, on group III mGlu receptor levels in the rat hippocampus: effects of ketamine, electroconvulsive shock therapy and fluoxetine treatment.
O' Connor RM; Pusceddu MM; Dinan TG; Cryan JF
Neuropharmacology; 2013 Mar; 66():236-41. PubMed ID: 22609536
[TBL] [Abstract][Full Text] [Related]
15. (
Zanos P; Highland JN; Stewart BW; Georgiou P; Jenne CE; Lovett J; Morris PJ; Thomas CJ; Moaddel R; Zarate CA; Gould TD
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6441-6450. PubMed ID: 30867285
[TBL] [Abstract][Full Text] [Related]
16. Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice.
Ago Y; Yano K; Araki R; Hiramatsu N; Kita Y; Kawasaki T; Onoe H; Chaki S; Nakazato A; Hashimoto H; Baba A; Takuma K; Matsuda T
Neuropharmacology; 2013 Feb; 65():29-38. PubMed ID: 23022081
[TBL] [Abstract][Full Text] [Related]
17. On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039.
Pałucha-Poniewiera A; Wierońska JM; Brański P; Stachowicz K; Chaki S; Pilc A
Psychopharmacology (Berl); 2010 Dec; 212(4):523-35. PubMed ID: 20703449
[TBL] [Abstract][Full Text] [Related]
18. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.
Lorrain DS; Schaffhauser H; Campbell UC; Baccei CS; Correa LD; Rowe B; Rodriguez DE; Anderson JJ; Varney MA; Pinkerton AB; Vernier JM; Bristow LJ
Neuropsychopharmacology; 2003 Sep; 28(9):1622-32. PubMed ID: 12825094
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists.
Koike H; Iijima M; Chaki S
Neuropharmacology; 2011 Dec; 61(8):1419-23. PubMed ID: 21903115
[TBL] [Abstract][Full Text] [Related]
20. Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression.
Koike H; Fukumoto K; Iijima M; Chaki S
Behav Brain Res; 2013 Feb; 238():48-52. PubMed ID: 23098797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
